InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,344.60
(
0.16%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rurik post# 13968

Tuesday, 11/08/2011 10:05:46 AM

Tuesday, November 08, 2011 10:05:46 AM

Post# of 80490

Rachel McMinn is invested in justifying her hold recommendation in the face of a sea of buy recommendations. The fact that she the lacks insight and the experience necessary to be a good biotech analyst even though she is good at collection numerical data doesn't stop Merrill hiring her.

In general, I don’t think much of sell-side analysts, but McMinn is one of the better analysts covering the biotech sector, IMO. She has made some especially good calls in the HCV arena.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up